176 related articles for article (PubMed ID: 21900519)
21. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
Espinel-Ingroff A; Arendrup MC; Pfaller MA; Bonfietti LX; Bustamante B; Canton E; Chryssanthou E; Cuenca-Estrella M; Dannaoui E; Fothergill A; Fuller J; Gaustad P; Gonzalez GM; Guarro J; Lass-Flörl C; Lockhart SR; Meis JF; Moore CB; Ostrosky-Zeichner L; Pelaez T; Pukinskas SR; St-Germain G; Szeszs MW; Turnidge J
Antimicrob Agents Chemother; 2013 Dec; 57(12):5836-42. PubMed ID: 24018263
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
23. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
[TBL] [Abstract][Full Text] [Related]
24. Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent
Espinel-Ingroff A; Sasso M; Turnidge J; Arendrup M; Botterel F; Bourgeois N; Bouteille B; Canton E; Cassaing S; Dannaoui E; Dehais M; Delhaes L; Dupont D; Fekkar A; Fuller J; Garcia-Effron G; Garcia J; Gonzalez GM; Govender NP; Guegan H; Guinea J; Houzé S; Lass-Flörl C; Pelaez T; Forastiero A; Lackner M; Magobo R
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0109321. PubMed ID: 34370582
[TBL] [Abstract][Full Text] [Related]
25. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
[TBL] [Abstract][Full Text] [Related]
26. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
Jang MJ; Shin JH; Lee WG; Kim MN; Lee K; Lee HS; Lee MK; Chang CL; Jang HC; Song ES; Kim SH; Shin MG; Suh SP; Ryang DW
Ann Lab Med; 2013 May; 33(3):167-73. PubMed ID: 23667842
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
[TBL] [Abstract][Full Text] [Related]
28. Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria.
Aigner M; Erbeznik T; Gschwentner M; Lass-Flörl C
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559257
[No Abstract] [Full Text] [Related]
29. Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare.
Lockhart SR; Pham CD; Kuykendall RJ; Bolden CB; Cleveland AA
Diagn Microbiol Infect Dis; 2016 Jan; 84(1):52-54. PubMed ID: 26429293
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
31. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
[TBL] [Abstract][Full Text] [Related]
33. Rezafungin
Helleberg M; Jørgensen KM; Hare RK; Datcu R; Chowdhary A; Arendrup MC
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015032
[TBL] [Abstract][Full Text] [Related]
34. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
[TBL] [Abstract][Full Text] [Related]
35. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
[TBL] [Abstract][Full Text] [Related]
36. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
37. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
Espinel-Ingroff A; Cantón E
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():3-9. PubMed ID: 21420570
[TBL] [Abstract][Full Text] [Related]
39. Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex.
Salsé M; Gangneux JP; Cassaing S; Delhaes L; Fekkar A; Dupont D; Botterel F; Costa D; Bourgeois N; Bouteille B; Houzé S; Dannaoui E; Guegan H; Charpentier E; Persat F; Favennec L; Lachaud L; Sasso M
Clin Microbiol Infect; 2019 Dec; 25(12):1546-1552. PubMed ID: 31082487
[TBL] [Abstract][Full Text] [Related]
40. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Dagi HT; Findik D; Senkeles C; Arslan U
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]